Logo
x

Search

Subscribe Now

ckd

Cara and Vifor's Korsuva (difelikefalin) Receive the US FDA's Approval for the Treatment of Moderate-to-Severe Pruritus Due to CKD in Patients with Hemodialysis

Cara and Vifor's Korsuva (difelikefalin) Receive the US FDA's Approval for the Treatment of Moderate-to-Severe Pruritus Due to CKD...

  • August 25, 2021
The US FDA's Rejects FibroGen's Roxadustat for the Treatment of Anemia Due to CKD

The US FDA's Rejects FibroGen's Roxadustat for the Treatment of Anemia Due to CKD

  • August 11, 2021
Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

  • January 13, 2021
Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

  • November 10, 2020
AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020

AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020

  • October 26, 2020
Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies

Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies

  • October 22, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.